To definitively ascertain the indispensable role of MZT2B in NSCLC progression, we employed CRISPR/Cas9 gene editing technology to achieve a complete knockout of MZT2B in primary pNSCLC1 cells. This evidence concerns the gene MZT2B and non-small cell lung carcinoma.